Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, is pleased to welcome Dr. Chandra Prakash, Ph.D., as ...

Cohort composition spans sterile small molecules, APIs, commercial cell-culture biologics, rare-disease drug substance, and CGT capacity across NY, NJ, IN, and NC manufacturing hubs. Eligibility ...

Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...

Elon Musk’s ex Ashley St. Clair claims she turned down a multi-million-dollar NDA from the newly minted trillionaire after giving birth to his 13th child. “It was a shock, especially the way in which ...

Taylor Swift and Travis Kelce’s love story includes an NDA. Ahead of the couple’s upcoming nuptials, TMZ reported on Saturday that guests who received a wedding invite are required to sign a ironclad ...

Blaze Media co-founder Glenn Beck told “Pod Force One” that President Trump once made him sign a non-disclosure agreement after giving him a private tour of the Lincoln Bedroom and telling him “some ...

The US Food and Drug Administration (FDA) is seeking comments on a pilot program where qualified external institutions will collaborate with sponsors to develop and review protocols for first-in-human ...

Mirum Pharmaceuticals MIRM and Incyte Corporation INCY have reported positive pivotal phase II results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral ALK2 ...

Anda Gansca of Knotch sits down at Cannes Lions 2026 to explain the rise of the “AI-native consumer”—and why the open web needs to reinvent itself to survive. She breaks down the “conversational web”: ...

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM); company also appoints Chief Commercial Officer DEL MAR, Calif., June 24, 2026 /PRNewswire/ -- CeleCor ...

DEL MAR, Calif., June 24, 2026 /PRNewswire/ -- CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's investigational heart-attack drug, zalunfiban ...